Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 2/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8752216 | 0.96 | L3MBTL1 (0.45) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL4186639 | 0.88 | CA1 (0.49) | CA1CA2CHRM3MEN1KMT2A | |
| SCHEMBL4186642 | 0.88 | CA1 (0.49) | CA1CA2CHRM3MEN1KMT2A | |
| SCHEMBL2769924 | 0.85 | L3MBTL1 (0.42) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL8717149 | 0.85 | CA1 (0.53) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL13377795 | 0.85 | CA1 (0.41) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL13377805 | 0.83 | CHRM3 (0.42) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL13460348 | 0.83 | CHRM3 (0.42) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL24114710 | 0.83 | L3MBTL1 (0.60) | CA1CA2L3MBTL1TDP1CHRM3 | |
| SCHEMBL7039897 | 0.82 | TK1 (0.37) | MEN1KMT2ATK1ALDH1A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363640-B1 | NUCLEIC ACID DERIVATIVES | BIO RAD LABORATORIES (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-1363640-B1 | NUCLEIC ACID DERIVATIVES | BIO RAD LABORATORIES (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7683164-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | BIO-RAD LABORATORIES INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7348148-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348148-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060148751-A1 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-7034131-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2006-04-25 | — | — | US | disclosed |
| US-20030191074-A1 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191074-A1 | Nucleic acid derivatives | NSUN2, POLRMT, ADAR | CA1 1765/4885CA2 2025/4885L3MBTL1 75/4885 |
| US-20060148751-A1 | Nucleic acid derivatives | NSUN2, POLRMT, ADAR | CA1 1925/4885CA2 2173/4885L3MBTL1 73/4885 |
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | POLRMT, NSUN2, RNGTT | CA1 1496/4885CA2 1731/4885L3MBTL1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.